sethcheetham.bsky.social
mRNA drug discovery | Deputy-Director BASE mRNA Facility | Associate Professor at the University of Queensland.
51 posts
991 followers
178 following
Regular Contributor
Active Commenter
comment in response to
post
Crucially, this approach doesn't require a new LNP, it works with FDA-approved formulations. We hope that this approach will enable targeted mRNA therapeutics for diverse diseases. Work led by Bettina Dietmair, James Humphries and Chris Howard. @basemrna.bsky.social
comment in response to
post
The technology is programmable and works with other targeting arms including anti-PSMA (highly expressed on prostate cancer cells) bispecifics. 6/
comment in response to
post
Bispecifics can be used by combining with the mRNA-LNP (pre-mixing) or the bispecific can be administered first (pre-targeting). 5/
comment in response to
post
As proof of concept we used anti-EGFR bispecifics to deliver mRNA to mouse breast cancer xenografts. The mRNA-payload (luciferase) is very efficiently delivered in vivo. 4/
comment in response to
post
To overcome this obstacle we developed bispecific antibodies that bind to PEG on the surface of LNPs and to cell-surface markers. 3/
comment in response to
post
Getting a high dose of mRNA to target tissues is one of the toughest problems for broad use of mRNA-LNP therapies. When administered systemically mRNA-LNPs go the liver with little delivery to other tissues. 2/
comment in response to
post
Happy to sure our protocol if helpful, just send me a DM
comment in response to
post
We use q5 which has a very low error rate. We've done a lot of ONTseq of plasmid and pcr templates and don't see any increase in error rate, but we see way better polyA integrity.
comment in response to
post
How much mRNA are you producing? We routinely use PCR to generate templates for up to 1-20mg productions. I know people that have done larger batches too.
comment in response to
post
There are some tweaks like segmented polyA tails that somewhat reduce deletions, but they're still very frequent. Worse, they are sometimes subclonal so sanger sequencing doesn't even detect the deletion. The field definitely needs better synthetic biology solutions.
doi.org/10.1261/rna....
comment in response to
post
Could be real though, polyA deletions in plasmids are really common and one of the reasons we switched to PCR-based templates.
comment in response to
post
@helengunter-mrna.bsky.social is the expert at this.
comment in response to
post
You might be a bit overqualified Scott ;)
comment in response to
post
@faulknerlab.bsky.social
comment in response to
post
This work was led by @helengunter-mrna.bsky.social who just joined @bsky.app. Follow her for all the latest on mRNA design and mRNA vaccine sequencing.
comment in response to
post
Try out the software here:
basefacility.org.au/software/
comment in response to
post
Sure thing Igor
comment in response to
post
Super cool work. I worked a lot with MS2 in my PhD and the background was always a challenge.
comment in response to
post
Sounds cool. Done
comment in response to
post
Done
comment in response to
post
Added
comment in response to
post
done
comment in response to
post
Done
comment in response to
post
Done
comment in response to
post
Hi, could you please me to your starter pack. I work on mRNA therapies for cancer.
comment in response to
post
Hi, could you please me to your starter pack. I work on mRNA therapies for cancer.